Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshiyuki Yamada has a total of 140 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnostic performance and clinical utility of open oral food challenges using double-blind, placebo-controlled food challenges as the reference standard: A systematic review

    by Yu Kuwabara, Norio Kawamoto, Takeshi Yamamoto, Tomoyuki Arima, Kazutaka Nogami, Shuichi Suzuki, Masaki Futamura, Yoshiyuki Yamada, Motohiro Ebisawa

  • Open Access

    Does avoiding percutaneous antigen exposure alleviate symptoms in adults with percutaneous sensitization-induced food allergy? A systematic review

    by Hiroki Murai, Yuri Takaoka, Makoto Nojo, Tetsuharu Manabe, Naoko Fusayasu, Kyoko Futamura, Masaki Futamura, Yoshiyuki Yamada, Motohiro Ebisawa

  • Open Access

    Experimental Extracorporeal Circulation System: A Pilot Study in Rats

    by Akira T. Kawaguchi, Kaori Inukai, Mayuko Shibata, Gen T. Kawaguchi, Kazuaki Sato, Taiga Aburaya, Jacob Bergsland, Yoshiyuki Yamada

    Background: Extracorporeal circulation (ECC) has become an important component in cardiac surgery, for cardiopulmonary support, and as a bridge to transplantation. Optimization of systems, components, and management requires further refinements using relevant ECC models. Methods: A miniature silicone membrane oxygenator with a surface area of 134 cm 2 and a pump‐head tube with internal dimension, ID 2.0 mm, was connected to the rat with a double‐lumen tube, where the inner silicone tube (ID 1.0 mm) was irrigated with temperature‐controlled water, serving as a heat‐exchanger. Results: The ECC system had a priming volume less than 1.5 mL yet developed a pulsatile flow up to 11.6 mL/min, or 40 mL/min/kg, for a 290‐g animal. The system kept sufficient gas exchange, sustained stable hemodynamics in heart failure, and induced hyperthermia (40°C) and hypothermia (20°C) successfully with long‐term survival. Conclusion: A silicone‐based closed ECC system for rodents was developed as an experimental platform to address controversies, optimize management, and test the feasibility of new systems, components, or concepts in ECC.

  • Open Access

    Symptom control and medication adherence in Japanese pediatric and adolescent asthma: A large-scale web-based cross-sectional survey

    by Shigemi Yoshihara, Toshiko Itazawa, Taiji Nakano, Daisuke Hayashi, Takumi Takizawa, Arshan Perera, Yoshiyuki Yamada

  • Real‐World Evaluation of Associations Between Regular Intake and Food Challenge Outcome in Children

    by Sayaka Hamaguchi, Limin Yang, Chisato Jimbo, Tomoki Yaguchi, Marei Omori, Kouhei Hagino, Daisuke Harama, Daichi Suzuki, Kotaro Umezawa, Fumi Ishikawa, et al.


  • Open Access

    Pediatric Asthma Management in Japan: A Large-scale, Cross-sectional Survey

    by Shigemi Yoshihara, Toshiko Itazawa, Taiji Nakano, Daisuke Hayashi, Takumi Takizawa, Arshan Perera, Yoshiyuki Yamada

    Background: Pediatric asthma remains a critical public health problem, particularly in Japan, where adherence to new treatment guidelines and effective medication use are inconsistent. Therefore, we aimed to evaluate the current management practices for pediatric asthma to identify areas for improvement and enhance future treatment approaches. Methods: We conducted a web-based cross-sectional survey involving caregivers of children and adolescents aged 0–19 years diagnosed with asthma at various medical institutions in Japan. The survey focused primarily on evaluating the control status of asthma in these patients and examining factors such as treatment adherence, environmental exposure, and the presence of allergic diseases. Results: The data showed that 65.9% of the patients received some form of asthma treatment; however, a significant proportion (26.2%) still experienced poor symptom control (n=2000). The most affected group were children aged 0–3 years. The analysis showed that environmental factors and coexisting allergic diseases notably influenced poor asthma control, although direct correlations with treatment adherence were not statistically significant. Conclusion: These findings highlight the substantial gap in the effective management of pediatric asthma, particularly in very young children. Notably, pharmacotherapy is essential; however, there is an urgent need to develop comprehensive treatment plans that address environmental and lifestyle factors. Future strategies should focus on personalized care tailored to each child’s specific need, incorporating medical and non-medical interventions to optimize asthma control and improve overall health outcomes.

  • Open Access

    In-depth proteomic profiles prior to symptom development in food protein-induced enterocolitis

    by Yuzaburo Inoue, Hironori Sato, Masaki Ishikawa, Yusuke Kawashima, Hiroki Kawamura, Mayumi Enseki, Yuka Osaki, Sachiko Kaburagi, Masayuki Akashi, Arisa Ito, et al.

    Not-yet-known not-yet-known not-yet-known unknown Background: The innate immune system is activated at the onset of food protein-induced enterocolitis syndrome (FPIES) symptoms. However, the precise mechanism through which this immune response is initiated remains unclear. Objective: We aimed to investigate the proteomic profile of FPIES during symptom development through in-depth serum and saliva proteomic analyses. Methods: We enrolled 17 patients with a previous diagnosis of egg yolk FPIES who underwent an oral food challenge test (OFC) with 5 g of heated egg yolk. Six patients showed positive OFC results, whereas 11 showed negative OFC results. Serum and saliva samples were collected before OFC and 1 and 2 h after ingestion. Serum was also collected at symptom onset. We analyzed serum and saliva peptides using data-independent acquisition-mass spectrometry and compared levels to identify protein groups and pathways important in FPIES symptom development. Results: We detected 4,138 and 7,202 proteins in the serum and saliva, respectively. The OFC-positive group exhibited 609 serum proteins with more than a two-fold change in expression 2 h after OFC, including proteasome subunits and neddylation-related proteins. We identified 304 proteins associated with symptom onset, including those related to the degradation response and neutrophil extracellular trap formation. Proteins related to neutrophil activation increased both in the serum and saliva, regardless of the onset of symptoms. Conclusion: Our findings suggest that changes in protein levels, including proteasome and neddylation-related proteins, may be involved in FPIES pathogenesis and warrant further investigation to address the growing clinical burden imposed by gastrointestinal allergies.

  • Open Access

    Cytokine profiling in 128 patients with transient abnormal myelopoiesis: a report from the JPLSG TAM-10 trial

    by Genki Yamato, Yusuke Tsumura, Hideki Muramatsu, Akira Shimada, Takahiro Imaizumi, Hiroyuki Tsukagoshi, Taeko Kaburagi, Norio Shiba, Yoshiyuki Yamada, Takao Deguchi, et al.

    Transient abnormal myelopoiesis (TAM) occurs in 10% of neonates with Down syndrome (DS). Although most patients show spontaneous resolution of TAM, early death occurs in ∼20% of cases. Therefore, new biomarkers are needed to predict early death and determine therapeutic interventions. This study aimed to determine the association between clinical characteristics and cytokine levels in patients with TAM. A total of 128 patients with DS with TAM enrolled in the TAM-10 study conducted by the Japanese Pediatric Leukemia/Lymphoma Study Group were included in this study. Five cytokine levels (interleukin-1b [IL-1b], IL-1 receptor agonist, IL-6, IL-8, and IL-13) were significantly higher in patients with early death than in those with nonearly death. Cumulative incidence rates (CIRs) of early death were significantly associated with high levels of the 5 cytokines. Based on unsupervised consensus clustering, patients were classified into 3 cytokine groups: hot-1 (n = 37), hot-2 (n = 42), and cold (n = 49). The CIR of early death was significantly different between the cytokine groups (hot-1/2, n = 79; cold, n = 49; hot-1/2 CIR, 16.5% [95% confidence interval (CI), 7.9-24.2]; cold CIR, 2.0% [95% CI, 0.0-5.9]; P = .013). Furthermore, cytokine groups (hot-1/2 vs cold) were independent poor prognostic factors in the multivariable analysis for early death (hazard ratio, 15.53; 95% CI, 1.434-168.3; P = .024). These results provide valuable information that cytokine level measurement was useful in predicting early death in patients with TAM and might help to determine the need for therapeutic interventions. This trial was registered at UMIN Clinical Trials Registry as #UMIN000005418.


  • Open Access

    Recent topics on gastrointestinal allergic disorders

    by Yoshiyuki Yamada

    Gastrointestinal (GI) allergies are broadly associated with food allergies and divided into groups based on the degree of allergen-specific immunoglobulin E (IgE) involvement: IgE-mediated, non-IgE-mediated, and mixed. Non-IgE-mediated GI food allergies are mostly observed in neonates and infants and include food protein-induced enterocolitis syndrome (FPIES), food protein-induced allergic proctocolitis (FPIAP), and food protein-induced enteropathy (FPE). In addition to the classical phenotype, unique phenotypes such as vomiting and bloody stool, suspected sepsis, and overlapping eosinophilic GI disorders (EGIDs) have increased in Japan over the past 2 decades. Some of these cases were defined as having chronic FPIES. More recently, cases of hen’s-egg FPIES in Japan have increased dramatically since 2018, albeit for unknown reasons. Typical mixed-type food allergies are EGIDs, characterized by prominent eosinophil infiltration in the GI tract leading to GI symptoms. EGIDs are broadly classified into eosinophilic esophagitis (EoE) and non-EoE EGIDs that involve the GI tract with the exception of the esophagus. Of the EGIDs, EoE is the best known, as the number of cases has increased dramatically in Western countries, whereas pediatric EoE remains rare in Asia and non-EoE EGIDs may be more prevalent in Japan. A recent Japanese national survey showed that pediatric non-EoE EGIDs were persistent and severe compared to those in adults, possibly requiring further effective therapeutic options. Among the EGIDs, FPIAP is pathologically diagnosed as an infantile form of eosinophilic colitis. In addition, recent FPIES and FPE cases also involved eosinophilic inflammation. Recent cases of GI allergies may be associated with type 2 inflammation. A better understanding of the interactions between GI allergies and type 2 inflammation may clarify the pathogenesis of the recent increase in GI allergies.


  • Open Access

    Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders

    by Naoya Arakawa, Hisako Yagi, Mariko Shimizu, Daisuke Shigeta, Akihiko Shimizu, Shigeru Nomura, Takumi Takizawa, Yoshiyuki Yamada

    A recent report showed that most pediatric cases of non-eosinophilic esophagitis (EoE) eosinophilic gastrointestinal disorders (EGIDs) (non-EoE EGIDs) are persistent and severe compared with those of EoE, thus requiring further effective therapeutic approaches. In this study, we present the first case based on a systematic search of non-EoE EGID for which tolerance to causative foods and histological and symptomatic improvements were achieved following dupilumab administration, after elimination diets and omalizumab and mepolizumab treatments. Driven by this case, we investigated the efficacies of biological treatments in non-EoE EGID cases based on the patient studied herein, and other patients identified in the conducted systematic review. Seven articles, including five different biologics, were reviewed. Both clinical efficacies and impact differences among the targeted molecules are demonstrated in this study. Our findings show that dupilumab may affect mechanisms that can suppress symptoms induced by offending foods that are different from those induced by other biologics as identified in the conducted systematic review. Additional studies are required to address the unmet needs of non-EoE EGID treatments.